<DOC>
	<DOC>NCT00985621</DOC>
	<brief_summary>The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis</brief_summary>
	<brief_title>Tanezumab In Osteoarthritis Of The Hip Or Knee</brief_title>
	<detailed_description>This study was terminated on 13 Dec 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>osteoarthritis of the knee or hip according to KellgrenLawrence xray grade of 2 pregnancy or intent to become pregnant BMI greater than 39 other severe pain, significant cardiac, neurological or psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>monoclonal antibody</keyword>
	<keyword>RN624</keyword>
	<keyword>PF-04383119</keyword>
	<keyword>nerve growth factor</keyword>
	<keyword>OA</keyword>
	<keyword>pain</keyword>
	<keyword>arthritis</keyword>
</DOC>